GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in human vaccines and cancer immunotherapies, announced that Chairman and CEO David Dodd will present at NobleCon21, the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference. The presentation is scheduled for December 3, 2025, at 3:00 pm ET at the Florida Atlantic University Executive Education Complex in Boca Raton, Florida.
The corporate update presentation comes at a critical time for vaccine development and cancer treatment research. GeoVax's lead clinical program, GEO-CM04S1, represents a significant advancement in COVID-19 vaccine technology, currently undergoing three Phase 2 clinical trials. These trials are evaluating the vaccine as a primary option for immunocompromised patients, including those with hematologic cancers, who have shown inadequate response to currently authorized COVID-19 vaccines. This development addresses a crucial gap in pandemic preparedness and protection for vulnerable populations.
For patients with chronic lymphocytic leukemia (CLL), the vaccine is being studied as a booster, potentially offering enhanced protection for this immunocompromised group. Additionally, the vaccine is being evaluated as a more robust and durable COVID-19 booster for healthy patients who previously received mRNA vaccines, which could lead to longer-lasting immunity against COVID-19 variants.
In oncology, GeoVax's lead clinical program involves Gedeptin®, a novel oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. This represents an innovative approach to cancer treatment that could expand options for patients with difficult-to-treat solid tumors.
The company is also advancing a vaccine targeting Mpox and smallpox, with recent regulatory guidance allowing the company to progress directly to Phase 3 clinical evaluation, bypassing Phase 1 and Phase 2 trials. This accelerated pathway could significantly speed up the development of important public health tools against these infectious diseases.
Interested investors and guests can register for the conference at a discounted rate using code GOVXNOBLECON through the registration portal. A high-definition video webcast of the presentation will be available the following day through www.nobleconference.com and www.channelchek.com, Noble Capital Markets' investor portal. The webcast will remain archived for 90 days following the event. Senior GeoVax management will also conduct one-on-one meetings with registered attendees during the conference. Additional information about the company's clinical trials and technology developments is available at www.geovax.com.
